Accessibility Menu
MariMed logo

MariMed(OTC) MRMD

Current Price$0.06
Market Cap$25.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-84%
5 Year-93%
1 Year-39%
1 Month-2%
MariMed last closing stock price
MetricPriceDate
Last closeUSD 0.062026-07-22
MariMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.27%USD 0.072026-07-15
1 month-2.42%USD 0.072026-06-22
3 month-18.35%USD 0.082026-04-23
Year to date-31.35%USD 0.092025-12-31
1 year-39.49%USD 0.112025-07-22
3 year-83.67%USD 0.402023-07-21
5 year-93.11%USD 0.942021-07-23
Since inception-83.75%USD 0.402017-05-12

MariMed Financials at a Glance

Market Cap

$25.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$161.51M

Net Income (TTM)

-$12.63M

EPS (TTM)

-$0.03

P/E Ratio

-2.03

Dividend

$0.00

Beta (Volatility)

0.46 (Low)

Price

$0.06

Volume

149,027

Open

$0.07

Previous Close

$0.06

Daily Range

$0.06 - $0.07

52-Week Range

$0.06 - $0.23

Estimated Earnings Date

Aug 12, 2026

MRMD News

Foolcom-Featured.png

MariMed (MRMD) Q2 EPS Jumps to Positive

Motley Fool Markets TeamAug 7, 2025
A family meeting with an advisor.

2 Underrated Growth Stocks That Could Double Your Money

David Jagielski, CPAJul 28, 2022
cannabis seller weighs cannabis

These 3 Trends Will Separate the Winners and Losers of Cannabis Stocks

Alex CarchidiNov 5, 2021
cannabis farmer gives thumbs up in a field

2 Cannabis Growth Stocks That Could Double By 2024

Alex CarchidiNov 2, 2021
GettyImages-1276431325

3 Cannabis Stocks That Could Easily Double By 2023

Rich DupreyOct 4, 2021
Multiple people looking at something on a cell phone.

2 Promising Growth Stocks to Buy Before 2022

David Jagielski, CPASep 24, 2021
GettyImages-581032281

2 Small Cannabis Companies Showing Huge Gains

James HalleyJul 23, 2021
A person examining a cannabis plant outdoors.

Is This the Most Underrated Pot Stock to Buy Right Now?

David Jagielski, CPAJul 21, 2021
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MariMed

MariMed produces cannabis products for medical and recreational use. Its edibles and infused products offer alternatives to traditional medicines. The company serves patients, adult consumers, and retail partners seeking regulated cannabis solutions.

Products and Services

  • Cannabis Flower & Concentrates:
  • Infused Edibles: Chewable tablets and drink mixes (Kalm Fusion), and fruit chews (Betty's Eddies), for consumers seeking alternatives to smoking.
  • Baked Goods: Brownies, cookies, and sweets (Bubby's Baked), targeting social and recreational users.
  • Cannabidiol (CBD) Formulations: Florance brand, for those seeking non-psychoactive cannabis benefits.
  • Licensing & Facility Leasing: Licenses brands and leases facilities to third parties, supporting industry partners.
  • Wholesale Product Sales: Products are sold through wholesale channels, accounting for 43.2% of Q2 2025 revenue.

Growth and Expansion

  • Acquired First State Compassion Center in Delaware in March 2025, expanding retail presence.
  • Purchased Allgreens Dispensary (Illinois) and MedLeaf (Maryland) in 2024, increasing market reach.
  • Entered management and licensing agreement with Standard Farms in Pennsylvania in September 2025.
  • Expanded product lines and distribution through new dispensaries and wholesale channels since 2023.

What Makes MariMed Stand Out

MariMed controls its supply chain, from cultivation to retail sales. The company develops proprietary brands and licenses them to partners. Its strategy centers on acquisitions, product innovation, and expanding retail and wholesale networks.

Five Things You Need to Know

  • Revenue was $40M in Q2 2025, down 2% from Q2 2024.
  • Gross profit was $16M in Q2 2025, down 5.2% year-over-year.
  • Retail sales accounted for 56.6% and wholesale for 43.2% of Q2 2025 revenue.
  • Net loss improved to $-1M in Q2 2025, from $-2M in Q2 2024.
  • Cash flow from operations was $297,000 in Q2 2025, down 90.7% year-over-year.

Bottom Line

MariMed has grown through acquisitions and product expansion, focusing on the U.S. cannabis market. The company balances retail and wholesale sales while navigating regulatory and operational challenges.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

923

CEO

Jon R. Levine

Website

www.marimedinc.com

Headquarters

Norwood, MA 02062, US

MRMD Financials

Key Financial Metrics (TTM)

Gross Margin

36.02%

Operating Margin

-0.57%

Net Income Margin

-7.82%

Return on Equity

-23.32%

Return on Capital

-1.36%

Return on Assets

-6.28%

Earnings Yield

-49.26%

Dividend Yield

0.00%

Payout Ratio

-2.30%

Stock Overview

Market Cap

$25.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

399.27M

Volume

149.03K

Avg. Volume

641.55K

Financials (TTM)

Gross Profit

$58.17M

Operating Income

-$923.00K

EBITDA

$10.77M

Operating Cash Flow

$7.35M

Capital Expenditure

-$1.27M

Free Cash Flow

$6.08M

Cash & ST Invst.

$7.94M

Total Debt

$91.21M

MariMed Performance Analysis

MariMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 134,010,00010.3%
20232023-12-31USD 148,598,00010.9%
20242024-12-31USD 157,709,0006.1%
20252025-12-31USD 159,826,0001.3%
MariMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.4%
Q32025-09-302.9%
Q42025-12-312.2%
Q12026-03-31-5.2%
MariMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.0482.5%
20232023-12-31USD -0.04N/A
20242024-12-31USD -0.03-25.4%
20252025-12-31USD -0.0412.8%
MariMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3076.9%
Q32025-09-30-127.3%
Q42025-12-31-56.0%
Q12026-03-3118.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$39.48M

+4.0%

Gross Profit

$15.28M

+0.9%

Gross Margin

38.69%

N/A

Market Cap

$25.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$36.30K

N/A

Employees

715

N/A

Net Income

-$3.79M

+30.6%

EBITDA

$3.26M

+68.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.94M

+13.4%

Total Debt

$91.21M

+4.2%

Accounts Receivable

$10.31M

+11.6%

Inventory

$39.30M

+4.6%

Long Term Debt

$83.98M

+6.8%

Short Term Debt

$7.23M

-18.4%

Return on Assets

-6.28%

N/A

Return on Invested Capital

-0.67%

N/A

Free Cash Flow

$576.00K

-43.9%

Operating Cash Flow

$949.00K

-26.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CXXIFC21 Investments Inc.
$0.22-0.05%
ELIXFElixxer Ltd.
$0.03+0.00%
LEEEFLeef Brands Inc.
$0.20-5.16%
VEXTFVext Science, Inc.
$0.17-7.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
SPCXSpace Exploration Technologies
$115.26-0.07%

Questions About MRMD

What is the current price of MariMed?

MariMed is trading at $0.06 per share.

What is the 52-week range for MariMed?

Over the past 52 weeks, MariMed has traded between $0.06 and $0.23.

How much debt does MariMed have?

As of the most recent reporting period, MariMed reported total debt of $98.14M.

How much cash does MariMed have on hand?

MariMed reported $7.94M in cash and cash equivalents in its most recent financial results.

What is MariMed’s dividend yield?

MariMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services